When is the sensitive estradiol test clinically necessary?

Order the sensitive assay when expected oestradiol is low — postmenopausal states, male hypogonadism, paediatric disorders, ovarian-reserve assessment, or monitoring aromatase-inhibitor therapy — and whenever precision at low concentrations affects clinical decisions.

How does menstrual cycle phase affect estradiol results?

Oestradiol varies widely across the menstrual cycle, rising in the late follicular phase, peaking at ovulation, and falling in the luteal phase. Specifying cycle day or last menstrual period enables phase-appropriate interpretation; baseline assessments are typically done on day 2–3.

Can a normal estradiol result exclude ovarian insufficiency or hypogonadism?

A single mid-range result does not exclude intermittent dysfunction. Ovarian insufficiency or early menopause can present with fluctuating oestradiol; interpretation requires correlation with FSH, LH, menstrual history, and sometimes serial sampling.

Why measure estradiol in men?

In men, oestradiol arises from peripheral aromatisation of testosterone and is essential for bone health, libido, and metabolic function. Measurement identifies oestradiol excess (obesity, liver disease, exogenous sources) or deficiency (severe hypogonadism), and guides management of osteoporosis, sexual dysfunction, or gynaecomastia.

Does obesity affect estradiol levels?

Yes. Adipose tissue aromatises androgens to oestrogens, raising oestradiol in obese individuals — particularly men and postmenopausal women. This can mask true hypogonadism or confound low-range interpretation, and should be considered alongside SHBG and clinical context.

How is estradiol used to monitor aromatase-inhibitor therapy?

Aromatase inhibitors suppress oestradiol synthesis in postmenopausal breast-cancer patients; treatment efficacy requires very low (often undetectable, <10 pg/mL) oestradiol. The sensitive LC-MS/MS assay is the only method precise enough to confirm adequate suppression.

Is fasting required for the estradiol test?

No. Oestradiol does not require fasting, though timing to menstrual cycle phase in premenopausal women is important for interpretation.

BML-HRF-028female hormonesUSA

Estradiol, Sensitive

Q: What is the difference between a sensitive estradiol test and a standard estradiol immunoassay?

The sensitive assay uses liquid chromatography-tandem mass spectrometry (LC-MS/MS), which accurately quantifies oestradiol at low concentrations. Standard immunoassays are unreliable below approximately 20–30 pg/mL, making the sensitive method essential for postmenopausal women, men, children, and aromatase-inhibitor monitoring.

Q: Is fasting required for the estradiol test?

No. Oestradiol does not require fasting, though timing to menstrual cycle phase in premenopausal women is important for interpretation.

The Estradiol, Sensitive test quantifies serum oestradiol by LC-MS/MS, the gold standard for low-range measurement in postmenopausal women, men, children, and patients on aromatase inhibitors. It is interpreted with FSH, LH, and menstrual history to assess ovarian reserve, hypogonadism, menstrual disorders, and hormone-therapy efficacy where conventional immunoassays lack precision.

Biomarkers

Blood (serum)

Sample

3–5 business days

Turnaround

Fasting

What is the Sensitive E2 test?

The Estradiol, Sensitive test quantifies serum oestradiol using liquid chromatography-tandem mass spectrometry, the gold-standard method for measuring low oestradiol concentrations that fall below the reliable detection range of conventional immunoassays. Practitioners order the sensitive assay when the expected oestradiol level is low or when precision at low concentrations is clinically important — postmenopausal women, men, prepubertal children, monitoring of aromatase-inhibitor therapy in breast cancer, and evaluation of ovarian suppression. This assay separates true clinical signal from assay noise. In premenopausal women with regular cycles, a standard immunoassay is often adequate, but the sensitive method is preferred when baseline or luteal-phase oestradiol is being tracked in fertility protocols, or when discordance between symptoms and results suggests assay interference. Oestradiol is rarely interpreted in isolation: it is read with FSH and LH to distinguish primary from secondary hypogonadism, with progesterone to assess luteal function, and with testosterone in the work-up of virilisation or polycystic ovary syndrome.

What does the Sensitive E2 test measure?

E2(Estradiol (Sensitive LC-MS/MS))

Range: Varies widely by sex, age, and menstrual phase; premenopausal follicular 19–144 pg/mL, mid-cycle peak 63–356 pg/mL, luteal 55–214 pg/mL; postmenopausal <32 pg/mL; adult males 10–40 pg/mL.Optimal: Optimal oestradiol levels are context-dependent: mid-follicular levels above 50 pg/mL predict adequate ovarian reserve in assisted reproduction; postmenopausal women on aromatase inhibitors should have undetectable or very low oestradiol (<10 pg/mL); men require a balance that supports bone and libido (typically 20–30 pg/mL) without feminisation.pg/mL / pmol/L

Oestradiol is the most potent endogenous oestrogen, synthesised primarily by ovarian granulosa cells under luteinising hormone control in premenopausal women, with smaller contributions from adipose aromatisation of androgens and, during pregnancy, from the placenta. In men it arises almost entirely from peripheral aromatisation of testosterone. Circulating oestradiol is bound predominantly to sex hormone-binding globulin and albumin, with 1–2% free. The sensitive LC-MS/MS assay reliably quantifies oestradiol across the low ranges seen in men, postmenopausal women, and prepubertal children, where older immunoassays lack adequate specificity and precision.

Oestradiol drives endometrial proliferation, secondary sexual characteristics, and bone mineralisation, and modulates cardiovascular, metabolic, and central nervous system function. Measurement is central to the evaluation of menstrual irregularities, ovarian reserve, hypogonadism, precocious or delayed puberty, and monitoring of aromatase-inhibitor therapy or gender-affirming hormone treatment. The sensitive assay is essential when concentrations are expected to be low — postmenopausal states, male hypogonadism, paediatric disorders, or aromatase-inhibitor efficacy — because conventional immunoassays produce unreliable results below approximately 20–30 pg/mL.

Why is the Sensitive E2 test ordered?

Postmenopausal women presenting with vasomotor symptoms, bone loss, or suspected oestrogen deficiency, where the sensitive assay confirms low oestradiol with precision
Men with suspected hypogonadism, low libido, erectile dysfunction, or osteoporosis, to measure oestradiol arising from aromatisation and distinguish it from testosterone deficiency
Monitoring of aromatase-inhibitor therapy in postmenopausal breast-cancer patients, where treatment efficacy depends on suppressing oestradiol to very low levels
Assessment of ovarian reserve and response in assisted-reproduction protocols, where day-3 oestradiol informs stimulation strategy
Evaluation of precocious puberty in girls or boys, and delayed puberty, where sex-steroid concentrations are low and require precise quantification
Investigation of menstrual irregularities, amenorrhoea, or suspected polycystic ovary syndrome, interpreted alongside LH, FSH, and androgens
Monitoring of gender-affirming hormone therapy, where reliable low-range measurement is needed in transmasculine patients on testosterone
Work-up of gynaecomastia in men or virilisation in women, where oestradiol excess or imbalance may be contributory

Sample collection and turnaround

Sample type

Blood (serum)

Fasting required

Collection method

Venipuncture at patient service centre

Turnaround

3–5 business days

Collection notes

Phlebotomy at the processing laboratory's draw site (LabCorp or Access Medical Laboratories, depending on routing). For premenopausal women, specify cycle day or date of last menstrual period to enable phase-appropriate interpretation. No special preparation required, but avoid sampling during or immediately after exogenous hormone administration when monitoring replacement therapy.

Specimen requirements

Minimum 0.5 mL serum (gel separator acceptable). Separate from cells within two hours and refrigerate or freeze; oestradiol is stable frozen for months. Note the performing laboratory for serial comparability, as LC-MS/MS assays and reference intervals differ between labs.

What can affect Sensitive E2 results?

variableSex hormone-binding globulin (SHBG) concentration

Total oestradiol reflects both bound and free hormone; changes in SHBG — caused by obesity, thyroid dysfunction, or oral oestrogen — alter total oestradiol without necessarily changing free, bioavailable hormone. LC-MS/MS measures total oestradiol; interpretation should consider SHBG when discordance with clinical picture exists.

elevatesMenstrual cycle phase and ovulation

Oestradiol rises sharply in the late follicular phase, peaks at ovulation, and falls after the LH surge. Timing the sample to cycle day (early follicular for baseline, mid-luteal with progesterone for corpus-luteum function) is critical to interpretation.

elevatesExogenous oestrogen therapy

Oral, transdermal, or parenteral oestrogen supplementation raises measured oestradiol; practitioners must distinguish endogenous production from replacement when monitoring therapy or investigating hypogonadism in treated patients.

elevatesObesity and increased aromatase activity

Adipose tissue aromatises androgens to oestrogens, so obese patients — especially men and postmenopausal women — have higher oestradiol than lean individuals, which can mask hypogonadism or confound interpretation of low-range results.

reducesAromatase inhibitors and selective oestrogen-receptor modulators

Aromatase inhibitors (anastrozole, letrozole, exemestane) suppress oestradiol synthesis; SERMs (tamoxifen, raloxifene) block receptors but may raise circulating oestradiol by disrupting feedback. The sensitive assay is essential to confirm inhibitor efficacy.

variableLiver disease and reduced SHBG synthesis

Severe liver disease lowers SHBG, which lowers total oestradiol even if free hormone is adequate, and impairs oestrogen clearance, which can raise it. Interpretation in cirrhosis requires clinical context.

What do Sensitive E2 results mean?

Elevated

Premenopausal: granulosa-cell or other oestrogen-secreting tumours (rare), exogenous oestrogen. Postmenopausal: ovarian tumour, adrenal tumour, exogenous oestrogen, incomplete aromatase-inhibitor suppression. Men: aromatase excess (obesity, liver disease, genetic aromatase excess syndrome), exogenous oestrogen or anabolic-steroid use, testicular or adrenal tumour. Markedly elevated oestradiol in the setting of low or suppressed gonadotrophins suggests autonomous production.

Normal

A normal oestradiol in the appropriate phase (follicular baseline in women, adult male range in men) supports intact hypothalamic-pituitary-gonadal axis function. However, a single mid-range result does not exclude intermittent anovulation, luteal-phase defects, or early ovarian insufficiency; serial sampling and correlation with gonadotrophins and clinical context are needed for definitive assessment.

Reduced

Premenopausal: primary ovarian insufficiency, hypothalamic amenorrhoea (low gonadotrophins, low oestradiol), hypopituitarism, anorexia nervosa, extreme exercise. Postmenopausal: physiological. Men: rarely isolated, but seen with severe primary hypogonadism and very low testosterone substrate for aromatisation. Low oestradiol with high FSH/LH indicates ovarian or testicular failure; low oestradiol with low FSH/LH indicates central hypogonadism.

Note: Oestradiol is a snapshot of a dynamic axis; interpret with menstrual history, FSH, LH, and sometimes progesterone and testosterone. Reference ranges vary by laboratory, assay platform, and sex/age/cycle phase. The sensitive LC-MS/MS method is required for low-range measurement; results from conventional immunoassays below 30 pg/mL should not be trusted. SHBG concentration affects total oestradiol; if clinical picture and laboratory result diverge, consider measuring free or bioavailable oestradiol or SHBG itself.

Frequently asked questions

The sensitive assay uses liquid chromatography-tandem mass spectrometry (LC-MS/MS), which accurately quantifies oestradiol at low concentrations. Standard immunoassays are unreliable below approximately 20–30 pg/mL, making the sensitive method essential for postmenopausal women, men, children, and aromatase-inhibitor monitoring.

How to access the Sensitive E2 test

The Sensitive E2 reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.

Create Free Account

About this page

Published: October 7, 2026

Last reviewed: October 7, 2026

References:

Rosner W, et al. Position statement: utility, limitations, and pitfalls in measuring testosterone — an Endocrine Society position statement. J Clin Endocrinol Metab. (2007)
Santen RJ, et al. Postmenopausal hormone therapy: an Endocrine Society scientific statement. J Clin Endocrinol Metab. (2010)
Stanczyk FZ, et al. Standardization of steroid hormone assays: why, how, and when? Cancer Epidemiol Biomarkers Prev. (2007)
Nelson LR, Bulun SE. Estrogen production and action. J Am Acad Dermatol. (2001)
NICE guideline NG23: menopause — diagnosis and management. (2015)

This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.

Related tests

female hormones

Progesterone

The progesterone test measures serum progesterone, the principal hormone of the luteal phase and early pregnancy. Its main clinical use is confirming ovulation, with a mid-luteal rise providing biochemical evidence that a corpus luteum has formed.

BML-HRF-009View reference →

male hormones

Total Testosterone

The total testosterone test measures the sum of free, albumin-bound, and SHBG-bound testosterone in serum. It is the first-line androgen assessment in males with suspected hypogonadism and in females with hyperandrogenism, requiring morning collection to account for diurnal variation and interpretation alongside SHBG, LH, and FSH to classify androgen disorders.

BML-HRM-006View reference →